Showing results (321-330 of 554) with videos related to
Sort By:
Pageof 56
Investigational New Drugs|January 28, 2021
A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapyToni K Choueiri, Michael B Atkins, Tracy L Rose, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2001
Patient preferences for adjuvant interferon alfa-2b treatmentK L Kilbridge, J C Weeks, A J Sober, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinomaJ S Du Bois, E G Trehu, J W Mier, et al.Journal for Immunotherapy of Cancer|July 15, 2020
Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspectiveCasey Quinn, Louis P Garrison, Anja K Pownell, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1993
Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effectsJ A Sosman, G R Weiss, K A Margolin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1993
Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanomaJ A Sparano, R I Fisher, M Sunderland, et al.European Urology|September 17, 2020
Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell CarcinomaSumanta K Pal, Bernard J Escudier, Michael B Atkins, et al.BJU International|March 17, 2010
Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapyToni K Choueiri, Meredith M Regan, Jonathan E Rosenberg, et al.Cancer Research|April 19, 2005
Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasionArnold H Zea, Paulo C Rodriguez, Michael B Atkins, et al.Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|June 1, 1991
Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphomaK A Margolin, F R Aronson, M Sznol, et al.Pageof 56